These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 29923083)
1. MicroRNAs in regulation of triple-negative breast cancer progression. Piasecka D; Braun M; Kordek R; Sadej R; Romanska H J Cancer Res Clin Oncol; 2018 Aug; 144(8):1401-1411. PubMed ID: 29923083 [TBL] [Abstract][Full Text] [Related]
2. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer. Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322 [TBL] [Abstract][Full Text] [Related]
3. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Chen LL; Zhang ZJ; Yi ZB; Li JJ Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698 [TBL] [Abstract][Full Text] [Related]
6. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway. Liu G; Wang P; Zhang H J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779 [TBL] [Abstract][Full Text] [Related]
7. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653 [TBL] [Abstract][Full Text] [Related]
8. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling. Wang Z; Wang X J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
10. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients. Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197 [TBL] [Abstract][Full Text] [Related]
11. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells. Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition. Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450 [TBL] [Abstract][Full Text] [Related]
14. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. Ji H; Sang M; Liu F; Ai N; Geng C Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator. Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250 [TBL] [Abstract][Full Text] [Related]
16. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652 [TBL] [Abstract][Full Text] [Related]
17. MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis. Wang J; Li M; Han X; Wang H; Wang X; Ma G; Xia T; Wang S Cell Death Dis; 2020 Jul; 11(7):500. PubMed ID: 32620748 [TBL] [Abstract][Full Text] [Related]
18. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis. Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859 [TBL] [Abstract][Full Text] [Related]
19. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer. Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY Cells; 2021 Sep; 10(10):. PubMed ID: 34685504 [TBL] [Abstract][Full Text] [Related]
20. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer. Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]